← Back to patent-cliff list
恩曲他滨/盐酸利匹韦林/富马酸替诺福韦二吡呋酯
Tier B — Position earlyEmtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate
Gilead Sciences Inc
Originator
2011
First approval
-
Expiry (public)
$1.46B ▲
Peak sales
化学药
Type
Targets：RT、HIV-1 RT、HBV pol
Brand：Complera/Eviplera、Complera、Eviplera
Indications (approved)：HIV感染
Regional status
US
批准上市
2011-08-10
EU
批准上市
2011-11-27
China
批准上市
2015-12-30
Japan
批准上市
2014-11-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate?
Approved indications include: HIV感染.
When does the Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate patent expire?
No public expiry year is available for Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate yet; this page updates once verified.
How do I get a quote for Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24